Skip to main content
Premium Trial:

Request an Annual Quote

Waban to Adapt Software for MetriGenix Microarrays

NEW YORK, March 25 -MetriGenix has signed on Waban Software to adapt its Waban Explorer software for use with Metrigenix' microarrays, the companies said today.

 

Waban Explorer is a data warehouse and integration system for drug discovery. The system integrates data from diverse sources such as OMIM and GenBank with data and analyses from researcher's assays, and is 21 CFR part 11 compliant. Under this collaboration, the software will be tailored to accept data from the 4D Array system, a honeycomb-like microarray with probes on the insides of channels.

 

MetriGenix, a Gaithersburg, Md., spin-out of Gene Logic, markets the 4D array system with genomic and proteomic content that is focused on assays for cancer, cardiovascular disease, CNS disease, and autoimmune ailments. The flow-through design of the chip is designed to speed hybridization and reduce assay time.

 

MetriGenix chose Waban because of the "system scalability" as well as their technological expertise and "vision," said MetriGenix CEO Andrew O'Beirne in a statement.

 

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.